MorphoSys AG has appointed Arndt Schottelius as its new chief development officer responsible for coordinating the group’s therapeutic antibody development activities including preclinical and clinical development. The appointment takes effect on 29 December 2008.
Dr Schottelius joins MorphoSys from Genentech Inc where he was director of immunology, tissue growth & repair early development and most recently, medical director, immunology development. In this last position, he directed late-stage clinical development for the anti-CD20 antibodies, rituximab and ocrelizumab, in rheumatoid arthritis.
In addition to acting as chief development officer, Dr Schottelius will also sit on MorphoSys’s management board.
Dr Schottelius received his PhD and MD degrees from the Albert-Ludwigs-Universität in Freiburg, Germany, and was a research fellow at the University of North Carolina at Chapel Hill, before moving on to industry.
Copyright 2008 Evernow Publishing Ltd